Key facts
- Xaira Therapeutics’s last known valuation is $3.5B (Aug 2025).
- It has raised $1.3B across 1 recorded rounds; the latest was Later Stage VC ($1.0B) in Apr 2024.
- Notable investors include Sequoia Capital, Lightspeed Venture Partners, SV Angel, New Enterprise Associates, F-Prime Capital — 20 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Xaira Therapeutics
Funding rounds
1 roundsAbout Xaira Therapeutics
Developer of life-changing medicines designed through the transformative power of artificial intelligence. The company develops computational methods and models, data sets, platforms, and processes to expand science's power to cure disease, enabling patients to leverage these approaches to create novel therapeutics.
- Industry
- Biotech
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2023
- Employees
- 170
- Website
- xaira.com/
- Ownership
- Privately Held (backing)
Xaira Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xaira Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xaira Therapeutics in its N-PORT filings yet. We sweep new filings monthly.